Thomas E. Polen Jr. - 01 Jun 2026 Form 4 Insider Report for BECTON DICKINSON & CO (BDX)

Reporting relationship: Chairman, CEO and President, Director
Issuer ticker: BDX
Reported as of: 01 Jun 2026
Net transaction value: -$404,511
SEC form: 4
Accepted by SEC: 03 Jun 2026, 12:44:24 UTC
Prior SEC filing: 11 Feb 2026
Source filing: View source filing
Reporting owner signature: Donna Kalazdy, by power of attorney from Thomas E. Polen, Jr.

Key filing fact

Thomas E. Polen Jr. filed Form 4 for BECTON DICKINSON & CO (BDX) on 03 Jun 2026.

Key facts

This page summarizes Thomas E. Polen Jr.'s Form 4 filing for BECTON DICKINSON & CO (BDX).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2026, 12:44.

Change

Previous filing in this sequence was filed on 11 Feb 2026.
Current net transaction value: -$404,511.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001621793 Primary reporting owner

Polen Thomas E Jr

Relationship: Chairman, CEO and President, Director
Address: C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES
Signature: Donna Kalazdy, by power of attorney from Thomas E. Polen, Jr.
Signature date: 03 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BDX transaction

Common Stock

Options Exercise

Transaction value
Shares: +20,209
Change %: +19%
Price: $126.16^*
Shares after: 125,680
Date: 01 Jun 2026
Ownership: Direct

BDX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -17,445
Change %: -14%
Price: $146.15^*
Shares after: 108,235
Date: 01 Jun 2026
Ownership: Direct

BDX transaction

Common Stock

Sale

Transaction value: $404,511
Shares: -2,764
Change %: -2.4%
Price: $146.35
Shares after: 110,163
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BDX transaction Derivative

Stock Appreciation Rights

Options Exercise

Transaction value
Shares: -20,209
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,209
Exercise price: $126.16
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request.

Footnote F2

Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person.

Footnote F3

Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp.

Footnote F4

The stock appreciation rights vested in four annual installments beginning November 26, 2017.

SEC remarks

The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2026.